NCT03558165View on ClinicalTrials.gov

Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

August 20, 2020

Study Completion Date

February 18, 2022

Conditions
Lung Cancer Stage IV
Interventions
DIAGNOSTIC_TEST

Oncomine Comprehensive Assay

Stage IV lung adenocarcinoma patients will have previously biopsied tumor tissue tested with the Oncomine Comprehensive Assay

Trial Locations (1)

Unknown

Princess Margaret Cancer Centre, Toronto

All Listed Sponsors
collaborator

Princess Margaret Hospital, Canada

OTHER

collaborator

The Princess Margaret Cancer Foundation

OTHER

lead

University Health Network, Toronto

OTHER

NCT03558165 - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay | Biotech Hunter | Biotech Hunter